AKRX stock news

Der geplante Antrag auf Gläubigerschutz drückt die Aktien von Akorn auf den niedrigsten Stand seit fast elf Jahren. Die Papiere des Pharmafirma fielen im vorbörslichen US-Geschäft am Donnerstag um 23 Prozent auf 1,12 Dollar. Read more
NEW YORK--(BUSINESS WIRE)--The U.S. District Court for the Northern District of Illinois denied defendant Akorn, Inc.’s motion to dismiss two securities fraud lawsuits brought by several investment funds represented by Lowenstein Sandler’s Securities Litigation Group, ruling that the funds’ claims can proceed against Akorn and its officers and directors because the complaints plausibly allege material misrepresentations and omissions concerning the company’s regulatory noncompliance, which led Read more
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc. Read more
AKRX earnings call for the period ending September 30, 2019. Read more
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Akorn (AKRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half results and raised 2019 guidance) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 14) Acer Therapeutics Inc (NASDAQ: ACER ) (reacted to second-quarter results) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akorn, Inc. (NASDAQ: AKRX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) aTyr Pharma Inc (NASDAQ: LIFE ) (reacted to second-quarter results) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cancer Genetics Inc (NASDAQ: CGIX ) Cellectis SA (NASDAQ: CLLS ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced $6.5 million common stock offering) DiaMedica Therapeutics Inc (NASDAQ: DMAC )(reacted to second-quarter results) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) GENFIT S A/ADR (NASDAQ: GNFT ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Medigus ADR (NASDAQ: MDGS ) Meridian Bioscience, Inc. Read more
The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The U.S. Food and Drug Administration is investigating data integrity issues at the company’s manufacturing plants, issuing two warning letters this year about potential regulatory shortcomings. Akorn is also feeling pressure from its lenders. The company said in its most recently-filed quarterly financial statement that it’s working on a refinancing deal, but said that if those negotiations fail, Akorn faces a default that “could materially affect the company’s business, financial position and results of operations.” Read more
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Generic pharmaceuticals manufacturer Akorn, Inc. (NASDAQ: AKRX) said Tuesday that it received a warning letter from the Food and Drug … Read more

95 Biggest Movers From Yesterday

05:01am, Thursday, 09'th May 2019
Gainers Corindus Vascular Robotics, Inc. (NYSE: CVRS) climbed 35.71 percent to close at $2.85 on Wednesday following Q1 results. Akorn, Inc. (NASDAQ: AKRX) … Read more

Akorn (AKRX) Q1 2019 Earnings Call Transcript

01:24pm, Wednesday, 08'th May 2019
AKRX earnings call for the period ending March 31, 2019. Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT